Neurotransmitters and neuropeptides in headache

Current Opinion in Neurology

Volumn 9, Issue 3, 1996, Pages 206-210

  Limmroth, Volker ^a,c   Cutrer, F Michael ^b   Moskowitz, Michael A ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CALCITONIN GENE RELATED PEPTIDE; ERGOTAMINE; NEUROPEPTIDE; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE DERIVATIVE; PROSTAGLANDIN SYNTHASE; SEROTONIN; SEROTONIN RECEPTOR; SUBSTANCE P; SUBSTANCE P ANTAGONIST; SUMATRIPTAN; VASOCONSTRICTOR AGENT;

BRAIN BLOOD VESSEL; HEADACHE; HUMAN; MENINX; MENSTRUAL IRREGULARITY; MIGRAINE; NEUROGENIC INFLAMMATION; REVIEW; SENSORY NERVE; TISSUE REPAIR; TRIGEMINUS GANGLION; WEIGHT GAIN;

EID: 0029902138     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199606000-00009     Document Type: Review

References (52)

1. Luschka H: The nerves of the dura mater [in German] Laupp: Tübingen, 1850.
2. Ray BS, Wolff HG: Experimental studies on headache: pain structures of the head and their significance in headache. Arch Surg 1940, 41: 813-856.
3. Mayberg MR, Langer RS, Zervas NT, Moskowitz MA: Perivascular meningeal projections from cat trigeminal ganglia: possible pathway of vascular headaches in man. Science 1981, 213:228-230.
4. Stricker S: Studies on the root vessel of the sciatic nerve [in German]. Sitzungsber Kaiserl Akad Wiss (Wien) 1876, 3:173-185.
5. Bruce NA: The relation of sensitive nerve endings to the process of inflammation [in German]. Arch Exp Pathol Pharmacol 1910, 63:424-433.
6. Markowitz S, Saito K, Moskowitz MA: Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neuroscience 1987, 7:4129-4136.
7. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC: Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991, 44:97-112.
8. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA: Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992, 48:187-203.
9. Goadsby PJ, Edvinsson L, Ekman R: Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol 1988, 23:193-196.
10. Buzzi MG, Carter WB, Shimizu T, Heath III H, Moskowitz MA: Dihydroergotamlne and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal slnus during electrical Stimulation of the trigeminal ganglion. Neuropharmacol 1991, 30:1193-1197.
11. Nozaki K, Moskowitz MA, Boccalini P: CP-93,129, Sumatriptan, dihydroergotamln block c-fos expression within rat trigeminal nucleus caudalls caused by chemical Stimulation of the meninges. Br J Pharmacol 1992, 106:409-415.
12. von Euler US, Gaddum JH: Unidentified depressor substance in certain tissue extracts. J Physiol 1931, 72:74-87.
13. Lembeck F: The question of central transmission of afferent Impulses: 3. Existence and role of substance P in the dorsal root of the spinal cord [in German]. Naunyn-Schmiedberg's Arch Exp Pathol Pharmacol 1953, 219:197-213.
14. Cuello AC, DelFiacco M, Paxinos G: The central and peripheral ends of the substance P-containing sensory neurons in the rat trigeminal system. Brain Res 1978, 152:499-509.
15. Lui-Chen LY, Man DH, Moskowitz MA: Pia arachnoid contains substance P originating from trigeminal neurons. Neuroscience 1983, 9:803-808.
16. Kessler W, Kirchhoff Ch, Reeh PW, Handwerker HO: Excitation of cutaneous afferent nerve endings in vitro by a combination of inflammatory mediators and conditioning effect of substance P. Exp Brain Res 1992, 91:465-476.
17. Uddman R, Edvinsson L, Ekman R, Kingman R, McCulloch J: Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985, 62:131-136.
18. Le Greves P, Nyberg F, Terenius L, Hökfelt T: Calcitonin gene related peptide is a potent inhibitor of substance P degradation. Eur J Pharmacol 1965, 115:309-311.
19. Church MK, Lowman MA, Robinson C, Holgate ST, Benyon RC: Interaction of neuropeptides with human mast cells. Int Arch Allergy Appl Immunol 1989, 88:70-78.
20. Shekhar YC, Anand IS, Sarma R, Ferrari R, Wahl PL, Poole-Wilson PA: Effects of prolonged infusion of human alpha-calcitonin gene related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. Am J Cardiol 1991, 67:732-736.
21. Saxena MA, Smith FL, Dunlow LD, Dombrowski DS, Welch SP: The hypothermic and antinociceptive effects of intrathecal injection of CGRP (8-37) in mice. Life Sci 1994, 55:1665-1674.
22. Goadsby PJ, Edvinsson L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33:48-56.
23. Yu X, Moskowitz MA: Neuropeptide Y inhibits neurogenic plasma extravasation in rat dura mater via prejunctional neuropeptide Y2 receptor coupled to pertussis toxin-sensitive G protein. Cephalalgia 1995, 15 (supp 14):103.
24. Edivinsson L, Goadsby PJ: Neuropeptides in migriane and cluster head• ache. Cephalalgia 1994, 14: 320-327. A comprehensive review of the neuroanatomy of the sympathetic, parasympathetic and trigeminal fibers that ennervate cerebral vessels and their possible roles in headache.
25. 1D-receptor genes. Trends Pharmacol Sei 1992, 13:152-155.
26. Buzzi MG, Moskowitz MA: The antimigraine drug, sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990, 99:202-206.
27. 1D-β receptor messenger RNA in human trigeminal ganglia.
28. Hamel E, Fan E, Linville D, Ting V, Villemure JG, Chia LS: Expression for the serotonin 5-hydroxytryptamine-1Dβ receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 1993, 44:242-246.
29. Ullmer C, Schmuck K, Kalkman HO, Lübbert H: Expression of serotonin • receptor mRNA in blood vessels. FEBS Letters 1995, 370:215-221. An extensive study carried out in order to identify all G-protein coupled 5-HT-receptor messenger RNAs expressed in whole blood vessels and various endothelial and smooth muscle cells of different species.
30. Macor JE, Blake J, Fox CB, Johnson C, Koe BK, Lebel LA, Morrone JM, Ryan K, Schmidt AW, Schulz DW, Zorn SH: Synthesis and serotonerglc pharmacology of the enantiomers of 3-[(N-methylpyrrolidin-2-yl)methyl]-5-methoxy-1H-indole: discovery of stereogenic differentiation in the aminoethyl side chain of the neurotransmitter serotonin. J Med Chem 1992, 35:4503-4505.
31. Lee WS, Moskowitz MA: Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 1993, 626:303-305.
32. Cutrer FM, Schoenfeld D, Limmroth V, Panahian N, Moskowitz MA: The • sumatriptan analog, CP-122,288 decreases c-fos expression in trigeminal nucleus following chemical stimulation of the meninges. Br J Pharmacol 1995, 114:987-992. This study showed the potent antinociceptive effect of the first Conformationally restricted sumatriptan analogue.
33. Beattie DT, Connor HE: The pre- and postjunctional activity of CP-122,288, a Conformationally restricted analogue of sumatriptan. Eur J Pharmacol 1995, 276:271-276.
34. 1D receptors: 5-carboxamldo-tryptamine, CP-122,288 and dihydroergotamine, but not sumatriptan, CP-93,129 or serotonin-5-O-carboxymethyl-glycyl-lodo-tyrosinamlde block durai plasma protein extravasation. Mol Pharmacol 1996 (In press).
35. Matsubara T, Moskowitz MA, Huang Z: UK-14,304 R(-)-a-methyl-histamine and SMS 201-995 block plasma extravasation within dura mater by prejunctional mechanisms. Eur J Pharmacol 1992, 224:145-150.
36. Buzzi MG, Sakas DE, Moskowitz MA: Indomethacin and acetylsallcytic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1969, 165:251-258.
37. Diener HC, Limmroth V: The management of migraine. Rev Contemp Pharmacother 1994, 5:271-284.
38. Sørensen KV: Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 1988, 78: 346-348.
39. Hering R, Kuritzky A: Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992, 12:81-84.
40. Jensen R, Brinck T, Oleson J: Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994, 44:647-651.
41. Coria F, Sempere AP, Duarte J, Claveria LE, Cabezas C, Bayon C: Low-dose sodium valproate in the prophylaxis of migraine. Clin Neuropharmacol 1994, 17:569-573.
42. A receptor agonists and modulators influence the trigeminal vascular system.
43. A receptors.
44. A-agonists on neurogenic inflammation within the rat meninges. Soc Neurosci Abstr 1995, 21:1348.
45. A receptors, located outside the blood-brain barrier.
46. Kaiser HJ, Meienberg O: Deterioration or onset of migraine under oestrogen replacement therapy in the menopause. J Neurol 1993, 240: 195-197.
47. Lundberg PO: Prophylactic treatment of migraine with flumedroxone. Acta Neurol Scand 1968, 45:309-326.
48. Watling KJ, Krause JE: The rising sun shines on substance P and related peptides. Trends Pharmacol Sci 1993, 14:81-84.
49. 1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacol 1994, 112:920-924.
50. 1 antagonist RPR100893 decreases c-fos expression in trigeminal nucleus caudalis following noxlous chemical meningeal stimulation. Neuroscience 1995, 64:741-750.
51. 1-antagonist in two established animal models in this extensive study.
52. Diener HC, for the RPR 100893/201 Migraine Study Group: Substance P antagonist RPR 100893/201 Is not effective in human migraine attacks. Sixth International Headache Research Seminar: Copenhagen, Denmark; 19 November 1995.